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Abstract
Background: Cats with pleural effusion represent common emergencies in small animal practice. The aim of this
prospective study was to investigate the diagnostic ability of a point-of-care ELISA (POC-ELISA) for the measurement of
N-terminal pro B-type natriuretic peptide (NT-proBNP) to differentiate cardiac from non-cardiac disease in cats with
pleural effusion. The sample material for use of this rapid test was either plasma or diluted pleural effusion.
Twenty cats with moderate to severe pleural effusion were prospectively recruited. The cats were grouped into two
groups, with or without congestive heart failure (CHF; N-CHF), after complete work-up. Blood and effusion were
collected in EDTA tubes. Plasma and pleural effusion supernatants were transferred into stabilizer tubes and frozen.
POC-ELISA for NT-proBNP was performed with plasma and diluted effusion (1:1). Quantitative NT-proBNP measurement
was performed in plasma and diluted and undiluted effusions.
Results: Six cats were assigned to the CHF group. Of the 14 cats in the N-CHF group, 6 had concurrent cardiac
abnormalities that were not responsible for the effusion. For the detection of CHF, the test displayed respective
sensitivities and specificities of 100% and 79% in plasma and 100% and 86% in diluted pleural fluid. Receiver operating
characteristic (ROC) analysis for quantitative NT-proBNP measurement of plasma and diluted and undiluted pleural
effusions displayed areas under the curve of 0.98, sensitivities of 100% and specificities of 86%. The optimum cut-off was
calculated at 399 pmol/l in plasma and 229 pmol/l in the diluted effusion and 467 pmol/l in the undiluted effusion.
Conclusions: POC-ELISA for NT-proBNP in both plasma and diluted pleural effusion was suitable to differentiate cardiac
from non-cardiac causes of feline pleural effusion. According to our results, use of pleural effusion is feasible, but dilution
of the effusion before measurement seems to improve specificity.
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Background
Due to severe dyspnea, cats with pleural effusion are
commonly presented to an emergency service. In
addition to feline infectious peritonitis (FIP), pyothorax,
neoplasia and idiopathic chylothorax, congestive heart
failure (CHF) represents a common underlying disease
[1, 2]. Thoracic radiographs are commonly performed
but do not enable differentiation between cardiac and
non-cardiac causes in cases where moderate to severe
pleural effusion is present [3]. Echocardiography is
helpful, but the availability of this diagnostic tool is
limited due to the need for trained staff and specialized
equipment. This makes decisions about the administra-
tion of further cause-specific therapies (especially
diuresis) difficult in these patients.
Cardiac biomarkers have been used with increasing
frequency to differentiate cardiac from non-cardiac dys-
pnea in small animal medicine. Studies have investigated
the utility of NT-proBNP as a biomarker in cats [4–11].
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The synthesis of its precursor, proBNP, increases in
response to myocardial wall stress. ProBNP is cleaved
by proteases into the biologically active form BNP
and the inactive NT-proBNP [12]. NT-proBNP is pre-
ferred as a biomarker due to its longer plasma half-
life and higher plasma concentrations, which was
proven experimentally in sheep [13] and is presumed
to be the same in other animals.
First generation enzyme-linked-immunosorbent assay
(ELISA) was used to measure the concentration of NT-
proBNP in both plasma [14, 15] and pleural fluid [15] to
differentiate between cardiac and non-cardiac causes of
pleural effusion in cats. This assay is not available as an
in-house test, and the sample has to be sent to an exter-
nal laboratory. A major disadvantage of this approach is
the delay of up to 72 h in obtaining the test results,
which makes this approach unsuitable for emergency
situations. Recently, a second-generation ELISA was de-
veloped and is available as a quantitative ELISA and as a
semiquantitative point-of-care (POC) test. The use of
this test was first reported in a publication investigating
the detection of moderate to severe occult cardiomyop-
athy in cats [16] and it was recently described for diag-
nosing CHF in feline population with pleural effusion
[17]. Specificity to differentiate CHF versus non-CHF in
cats with pleural effusion was low with 64.7% for the
POC test, which is likely due to a low transition point
from negative to positive of 150 to 200 pmol/l according
to the study [17]. Dilution of the pleural effusion to re-
duce the number of false positive results could be a
method to improve specificity. The aim of our study was
to investigate the usefulness of diluted pleural samples
for measurement of NT-proBNP POC-ELISA to differ-
entiate cardiac from non-cardiac causes of moderate to
severe pleural effusion in cats. The secondary aim was to
confirm the results of the previous study about the use
of quantitative and POC-Test in plasma in a more
severely diseased group of cats.
Methods
Cats with pleural effusion were consecutively included
in the prospective study between March 2013 and April
2014. The following inclusion criteria had to be fulfilled:
1. Presence of relevant clinical signs leading to
admission to the intensive care unit (ICU);
2. Radiographic confirmation of moderate to severe
pleural effusion (obliterated cardiac and
diaphragmatic borders) [18];
3. Echocardiography request by the primary clinician.
Radiography was performed either by the referring vet-
erinarian or at presentation to the clinic. Initial echocar-
diography was performed either by a board-certified
cardiologist or under his supervision by a cardiology
resident or by a board-certified specialist in critical care
to confirm the presence of pleural effusion and to clas-
sify the patient as being in congestive heart failure
(CHF) or having a non-cardiogenic cause of pleural effu-
sion (N-CHF). The group assignment (CHF versus N-
CHF) was performed by a board-certified cardiologist
according to full echocardiogram, history, physical
examination and any additional work-up. Patients with
CHF underwent complete echocardiographic examin-
ation (including Doppler-echocardiography and pulsed
wave Tissue Doppler Imaging), ECG and Doppler-based
blood pressure measurement. Underlying heart disease
was classified according to the echocardiography results
by a board-certified cardiologist. Cardiomyopathies were
divided in 5 possible types according to published cri-
teria [19]: hypertrophic cardiomyopathy (HCM), restrict-
ive cardiomyopathy (RCM), dilated cardiomyopathy
(DCM), arrhythmogenic right ventricular cardiomyop-
athy (ARVC) and unclassified cardiomyopathy (UCM).
Main echocardiographic criteria were: M-mode derived
diameter of left ventricular free wall and septum (cut off
>6.0 mm) for diagnosis of HCM [20], right ventricular
diameter (cut off >8.3 mm) [20] for right ventricular
dilation; maximum left atrial dimension in B-mode in a
long axis view (cut off >15.8 mm) [21] for left atrial
dilation. Right atrial size was classified subjectively.
Concurrent cardiac abnormalities in patients with
non-cardiac causes of pleural effusion (N-CHF group)
were also recorded. Thoracocentesis was performed in
all cats followed by pleural fluid analysis and cytological
examination. In addition, a complete blood count and a
biochemical panel were performed in all cats. After ini-
tial stabilization, the diagnostic work-up was performed
based on the assignment to one of the two groups. In
the N-CHF group, diagnostic investigation into the
underlying non-cardiogenic disease was tailored to the
individual patient. This included laboratory investiga-
tions (pleural fluid analysis, cytology of fine needle
aspirates, blood examinations) and diagnostic imaging
modalities (radiography, ultrasound).
Blood for NT-proBNP measurement was collected by
venipuncture in EDTA-tubes. Pleural fluid samples were
also placed in EDTA tubes and subsequently treated in
the same way as blood samples. Sampling of blood and
pleural effusion had a maximum time difference of 1 h.
All samples in the EDTA tubes were centrifuged at 9000
x g for 1 min within 30 min of collection. EDTA plasma
and EDTA pleural fluid supernatant were then placed in
specific tubes containing a protease inhibitor mixture1
and were frozen at −20 °C for up to one week and at
−80 °C thereafter.
A POC-ELISA2 for feline NT-proBNP was performed
on each sample; this test had a transition point from
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negative to positive of 200 pmol/l according to the
manufacturer. Undiluted plasma and pleural fluid sam-
ples diluted with an equal amount of NaCl 0.9% were
analyzed. The POC-ELISA was performed by one inves-
tigator according to the manufacturer’s guidelines.3
Three drops of the sample and five drops of the assay
conjugate were mixed in a tube, and the mixture was
then poured into the POC-ELISA sample well. When
the sample-conjugate mixture reached the indicator win-
dow, the device was activated by the operator. After
10 min of incubation, the color density of the sample
and the reference spot were evaluated. The analysis was
performed using an automated optical density reader4
followed by visual inspection. The reader gives a result
classifying the test as either normal or abnormal accord-
ing to relative optical density. Immediately afterwards
digital images of the POC-ELISA were obtained using
a standard scanner at 600 dots per inch. These pic-
tures in the original size of the POC ELISA were
inspected by one investigator blinded to the results of
echocardiography and interpreted according to the
manufacturer’s guidelines for visual inspection. The
results were considered normal if the sample spot
was lighter than the reference spot and abnormal if it
was equal or darker.
In addition, the following samples were shipped frozen
to a commercial laboratory5 and were quantitatively ana-
lyzed using a previously described feline NT-proBNP
test6 [22] by laboratory technicians blinded to the final
diagnosis: EDTA plasma, pleural fluid supernatant, and
pleural fluid supernatant diluted 1:1 with 0.9% saline so-
lution refrozen after POC analysis. Samples with NT-
proBNP concentrations below the lower detection limit
(24 pmol/l) were reported as 17 pmol/l (lower detection
limit/
ﬃﬃﬃ
2
p
) [23] for statistical purposes. Samples with NT-
proBNP concentrations greater than the upper detection
limit of the test (1500 pmol/l) were diluted 1:2 with a fe-
line NT-proBNP diluent to obtain a result.
To evaluate the effect of dilution of the effusion sam-
ples, the ratio between the NT-proBNP concentration in
the paired undiluted and diluted samples was calculated
for all samples with NT-proBNP concentrations within
the detection limit of the assay.
Due to the small group size of the CHF group, non-
Gaussian distribution was assumed. Descriptive statistics
included frequencies for categorical variables and me-
dian and range for continuous variables. The data were
compared between groups (CHF versus N-CHF) using
the Mann-Whitney U test. Proportions were compared
using Fisher’s exact test. The sensitivity and specificity
and their 95% confidence interval (CI) for diagnosing
CHF were calculated. Quantitative NT-proBNP values
were graphically depicted as scatter plots of individual
data points and were analyzed with receiver operator
characteristic (ROC) analysis to determine the ability of
NT-proBNP to diagnose CHF. The area under the curve
(AUC) was used as a summary measure and quantifica-
tion of diagnostic accuracy for NT-proBNP to predict
CHF. The cut-off value was chosen based on the highest
Youden index (Y = sensitivity + specificity - 1) [24]. Stat-
istical analysis was performed using commercially avail-
able software.7 P values ≤ 0.05 were considered
significant.
Results
Twenty cats were included in this study. Fourteen cats
were classified as N-CHF and 6 as CHF. In the N-CHF pa-
tients, the following underlying diseases were diagnosed:
neoplasia (n = 7), septic pyothorax (n = 3), hemothorax
caused by chronic pleuritis (n = 1), feline infectious peri-
tonitis (n = 1), pancreatitis (n = 1) and steatitis (n = 1). Six
N-CHF patients had the following concurrent cardiac ab-
normalities: right atrial and ventricular dilation (n = 4),
HCM (n = 1), and UCM (n = 1). A board-certified cardi-
ologist judged that these changes were not severe enough
to cause pleural effusion. In cats with CHF, the diagnoses
were: HCM (n = 2), UCM (n = 2), DCM (n = 1), double
chambered right ventricle (n = 1).
Patient data are shown in Table 1, and echocardio-
graphic data in Table 2. There were no significant
differences concerning sex distribution, age or body
weight between the groups. Additionally, no significant
differences were found regarding heart and respiratory
rates. Body temperature was significantly lower in cats
with CHF (p = 0.043).
In both groups, there was one patient each with
heart murmur, gallop rhythm and arrhythmia. The
proportion of cats with abnormal auscultation find-
ings was not significantly (p = 0.32) different between
the N-CHF (3/13; 23%) and CHF groups (3/6; 50%).
The sample storage times ranged between 2 and
409 days. For both plasma and diluted pleural
effusion, there was no difference in the interpretation
between visual inspection and automatic reading in
the POC analysis.
When testing the diluted pleural effusion, 2/14 (14%)
cats in the N-CHF group and 6/6 (100%) cats with CHF
were positive on the POC test, which led to a sensitivity
of 100% (95% CI: 54.1% to 100%) and a specificity of
85.7% (95% CI: 57.2% to 98.2%) for a diagnosis of CHF.
Likewise, the median NT-proBNP concentration in di-
luted pleural effusion (Fig. 1) was significantly (p =
0.0011) different between the N-CHF and CHF cats
(47 pmol/l, range: 17–329 pmol/l versus 924.5 pmol/l,
range 249–1162 pmol/l). The AUC was 0.98 (95% CI:
0.92–1.00), and the optimal cut-off of 229 pmol/l had a
sensitivity of 100% (95% CI: 54.1% to 100%) and a speci-
ficity of 85.7% (95% CI: 57.2% to 98.2%). The use of
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200 pmol/l (transition point of the POC test) as a cut-off
for quantitative testing led to a sensitivity of 100% (95%
CI: 54.1% to 100%) and a specificity of 78.6% (95% CI:
49.2% to 95.3%).
Three out of 14 (21%) cats in the N-CHF group and 6/6
(100%) cats with CHF were positive on the POC test when
plasma samples were evaluated, which resulted in a sensi-
tivity of 100% (95% CI: 54.1% to 100.0%) and a specificity
of 78.6% (95% CI: 49.2% to 95.3%) for the diagnosis of
CHF for the cause of pleural effusion. The quantitative
values of plasma NT-proBNP (Table 1, Fig. 2) were signifi-
cantly (p = 0.0011) different between the N-CHF (median:
144.5 pmol/l; range: 17–552) and CHF cats (median
1698 pmol/l; 459–1942 pmol/l). The AUC was 0.98 (95%
CI: 0.92–1.00), and the optimal cut-off of 399 pmol/l gave
a sensitivity of 100% (95% CI: 54.1% to 100%) and a speci-
ficity of 85.7% (95% CI: 57.2% to 98.2%).
Three cats in the N-CHF group with concurrent car-
diac abnormalities (1 with HCM, 2 with right heart dila-
tion) had quantitative test results higher than 200 pmol/l
in both diluted pleural effusion and in the plasma (s.
Figs. 1 and 2). All three cats had positive POC results in
plasma, and two of them also had positive results in
diluted pleural effusion. The diluted pleural effusion
sample that tested negative by POC-ELISA had a NT-
proBNP concentration of 209 pmol/l, which is just above
the supposed transition point of the POC-test.
The quantitative NT-proBNP measurements were also
performed with undiluted pleural effusion. Cats in the
N-CHF group had significantly (p = 0.0011) lower
median NT-proBNP values than did cats in the CHF
group (108.5 pmol/l, range: 17–732 versus 1875 pmol/l,
range 509–2077 pmol/l). The AUC was 0.98 (95% CI:
Table 1 Summary of the data in two groups of cats without (N-CHF) or with (CHF) congestive heart failure
N-CHF (n = 14a) CHF (n = 6) p-value
Breeds DSH (8)
Crossbreed (2)
Maine Coon (1)
Siamese (1)
Persian (1)
Balinese (1)
DSH (4)
Maine Coon (1)
Bengal (1)
–
Sex (m/f) 6/8 3/3 1.0
Age (year) 8.0 (0.8–12.9) 8.4 (2.3–16.9) 0.77
Body weight (kg) 4.2 (2.6–6.0) 4.8 (2.9–7.7) 0.41
Heart rate (/min) 188 (160–240)a 195 (150–220) 0.93
Respiratory rate (/min) 60 (36–100)a 60 (28–80) 0.64
Temperature (°C) 38.7 (36.5–40.0)a 37.2 (36.3–38.2) 0.043
Pathological cardiac auscultation 3/13a 3/6 0.32
NT-proBNP (pmol/l) (median, range) Pleural effusion
1:1 diluted
47 (17–329) 924.5 (249–1162) 0.0011
NT-proBNP (pmol/l) (median, range) Pleural effusion 108.5 (17–732) 1875 (509–2077) 0.0011
NTproBNP (pmol/l) (median, range) Plasma 144.5 (17–552) 1698 (459–1942) 0.0011
aclinical data (heart rate, respiratory rate, temperature, and auscultation) were missing in one cat due to computer problems
DSH Domestic Short Hair, m male, f female
Table 2 Echocardiographic findings in two groups of cats
without (N-CHF) or with (CHF) congestive heart failure
N-CHF (n = 14) CHF (n = 6)
2D long axis LAD (mm)a 14.0 (8.9–22.0) 19.0 (8.2–41.0)
RA increasedb 4 3
M-mode long axis IVSd (mm)a 4.6 (3.7–6.7) 4.9 (2.8–7.9)
LVWd (mm)a 5.0 (3.4–7.7) 5.2 (3.1–8.6)
RVDd (mm) 5.9 (2.1–11.0) 7.5 (3.7–13.0)
LAD left atrium systolic diameter, RA subjective right atrium size, IVSd
interventricular septum diastolic diameter, LVWd left ventricular wall diastolic
diameter; a = median (range); b number of patients
Fig. 1 Quantitative NT-proBNP values in diluted pleural effusion. There
was a significant difference (p = 0.0011) between the N-CHF and CHF
cats. N-CHF = cats without congestive heart failure; CHF = cats with
congestive heart failure. The dashed line represents the calculated best
cut-off of 229 pmol/l. The dotted line represents the transition point of
the POC-ELISA of 200 pmol/l
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0.92–1.0), and the cut-off of 467 pmol/l yielded a sensi-
tivity of 100% (95% CI: 54.1% to 100%) and a specificity
of 85.7% (95% CI: 57.2% to 98.2%). The use of
200 pmol/l as a cut-off value gave a sensitivity of 100%
and a specificity of 64.3%.
In 12 cats, the NT-proBNP concentrations in diluted
and undiluted effusion samples were between the lower
and upper detection limits of the quantitative test. In
these patients, the ratios between the paired samples of
the quantitative NT-proBNP measurements in undiluted
and diluted pleural effusion were calculated and had a
mean of 2.23 (standard deviation 0.23).
Discussion
In the present study, POC-ELISA for NT-proBNP was
able to differentiate between cardiac and non-cardiac
causes of pleural effusion in cats using either plasma or
diluted pleural effusion samples. In addition, there was
significant agreement between automated and optical
evaluation as described earlier [16], which makes this
test helpful for routine use in general practice.
Our study supported recent results reported with
plasma samples [17] as the POC-ELISA performed com-
parably in both studies with excellent sensitivity (100%
(own study) versus 95.2% [17]) and good specificity
(78.6% (own study) versus 87.5% [17]). Dilution of the
pleural effusion samples resulted in a high sensitivity as
described for undiluted samples [17] (100% each). The
previous study that did the measurement in undiluted
pleural effusion had a low specificity of 64.7% (95% CI:
41.3% to 82.7%) [17]. Our results showed a specificity
85.7% (95% CI: 57.2% to 98.2%) in diluted samples. Be-
cause there was a wide overlap between the confidence
intervals, the significance of this difference has to be
proven in a larger number of cases.
Our study design was similar to earlier studies using
the first generation test [14, 15] and to a previous study
using the second generation ELISA [17]. The main dif-
ference in our study is the use of diluted pleural effusion.
The rationale for dilution was the need to reduce NT-
proBNP concentrations in the pleural fluid. Two studies
[15, 17] showed higher concentrations of NT-proBNP in
pleural effusion compared with plasma, and approxi-
mately one-quarter [15] or more [17] of the pleural fluid
samples in the non-cardiac cases had NT-proBNP values
above the reported transition point of the POC test
(200 pmol/l). The dilution resulted in slightly lower con-
centrations of NT-proBNP in the diluted material than
expected by calculation (ratio between paired samples of
undiluted and diluted effusion of 2.2 instead of 2.0). This
might have been caused by sample handling and degrad-
ation or a matrix effect of the diluent. Finally, the dilu-
tion seemed to be effective, as 5/14 non-cardiac cats had
values above 200 pmol/l in undiluted samples in contrast
to 3/14 cats in diluted samples. None of the cardiac cats
had values lower than 200 pmol/l after dilution; this
trend has to be proven in a larger group of cats. The
specificity for quantitative measurement of diluted
pleural effusion at a cut off at 200 pmol/l was 78.6%,
and this was slightly higher for the POC test (85.7%).
The reason for this was that one cat that had a NT-
proBNP concentration of 209 pmol/l tested negative
with the POC test. It seems that the transition point in
our batch lay between 209 pmol/l (highest quantitative
value with negative POC test) and 249 pmol/l (lowest
quantitative value with positive POC test). Compared
with an earlier study with an approximate transition
point of 150 pmol/l [16], this value was markedly in-
creased. For future use, it seems desirable to know the
switch point of the actually utilized batch to adapt the
dilution factor.
The second generation quantitative NT-proBNP assay
had good performance in the present as well as in a pre-
vious study [17]. The cut off values were higher in our
study both in plasma (399 pmol/l versus 199 pmol/l)
and in pleural effusion (467 pmol/l versus 240 pmol/l).
This discrepancy may be explained by small group sizes
and differences in selection of cases. While the other
study [17] recruited all cases independent of the grade of
pleural effusion, we only recruited symptomatic cases
with moderate to severe effusion. With the correspond-
ing cut offs in both studies, the sensitivity (95–100%)
was excellent, and the specificity (77–86%) was good in
both samples.
POC-ELISA and quantitative testing were both suit-
able as screening tests due to the high sensitivity in our
study and the earlier study [17]. The limited specificity
was probably caused by the number of cases with non-
cardiogenic pleural effusion and concurrent cardiac
Fig. 2 Quantitative NT-proBNP values in plasma. There was a significant
(p= 0.0011) difference between N-CHF and CHF cats. N-CHF = cats with-
out congestive heart failure; CHF = cats with congestive heart failure. The
dashed line represents the calculated best cut-off of 399 pmol/l. The dot-
ted line represents the transition point of the POC-ELISA of 200 pmol/l
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abnormalities (6/14 in our study, more than 25% in the
earlier study [17]). Many of the quantitative samples in
our study (3/6 plasma and 4/6 pleural effusion samples)
displayed concentrations above 200 pmol/l. Comparable
results were not reported in the other study [17], but the
findings may have been similar. We found NT-proBNP
elevations in cats with severe as well as mild cardiac
changes. In the more severely affected cases, the cause
for NT-proBNP elevation was probably the cardiac wall
stress itself, as described for cardiomyopathy in cats [4,
7, 11, 16], primary heart disease in dogs (e.g., DCM and
valve disease) [25, 26] and pulmonary hypertension or
embolism in dogs [27, 28]. In mildly affected cases, the
elevation could be caused by concurrent cardiac or other
disease processes as described for inflammatory condi-
tions in humans [29], dogs8 [27] and cats [14] or malig-
nancy in humans [30]. Increased NT-proBNP
concentration has also been described in cats with ad-
vanced kidney disease [31], but none of our cats dis-
played comparable severe renal impairment.
Study limitations
The major limitation of the study was the small number
of patients, especially in the CHF group. Blood pressure
was not routinely measured in non-cardiac cats.
Examination of the pleural fluid was not considered in
the data interpretation but could aid in establishing the
diagnosis, e.g., in cats with pyothorax.
POC-ELISA in pleural effusion was only evaluated in
diluted but not undiluted samples. Comparison of un-
diluted and diluted pleural effusion with the POC-ELISA
in the same patient could have shown more clearly the
effect of dilution on the specificity.
We measured all of our samples on the POC-ELISA in
a batch, and it would be better to test each patient imme-
diately after sampling. This was not possible, as the test
was not available at the beginning of patient recruitment.
To avoid any influence of any freeze-thaw cycles, sim-
ultaneous measurements of quantitative NT-proBNP
would have been ideal.
Conclusions
In this small number of patients using plasma and di-
luted pleural effusion, NT-proBNP POC-ELISA was ap-
propriate to differentiate between cardiac and non-
cardiac underlying disease in cats with moderate to se-
vere pleural effusion. Using pleural effusion, 1:1 dilution
with 0.9% NaCl is feasible and has the potential to
improve the diagnostic accuracy of this test with this
sample material.
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